AMELORATIVE AND HEPATOPROTECTIVE EFFECTS OF FISETIN ON ACUTE MURINE TOXOPLASMOSIS
ELMEHY, D., SALAMA, A., SOLIMAN, N., ELKHOLY, R., TAHOON, D., MADY, R., GAMEA, G. (2021). AMELORATIVE AND HEPATOPROTECTIVE EFFECTS OF FISETIN ON ACUTE MURINE TOXOPLASMOSIS. EKB Journal Management System, 51(1), 79-88. doi: 10.21608/jesp.2021.165943
DALIA A. ELMEHY; AMINA M. SALAMA; NEMA A. SOLIMAN; REEM A. ELKHOLY; DINA M. TAHOON; RASHA F.Department of Medical Parasitology MADY; GHADA A. GAMEA. "AMELORATIVE AND HEPATOPROTECTIVE EFFECTS OF FISETIN ON ACUTE MURINE TOXOPLASMOSIS". EKB Journal Management System, 51, 1, 2021, 79-88. doi: 10.21608/jesp.2021.165943
ELMEHY, D., SALAMA, A., SOLIMAN, N., ELKHOLY, R., TAHOON, D., MADY, R., GAMEA, G. (2021). 'AMELORATIVE AND HEPATOPROTECTIVE EFFECTS OF FISETIN ON ACUTE MURINE TOXOPLASMOSIS', EKB Journal Management System, 51(1), pp. 79-88. doi: 10.21608/jesp.2021.165943
ELMEHY, D., SALAMA, A., SOLIMAN, N., ELKHOLY, R., TAHOON, D., MADY, R., GAMEA, G. AMELORATIVE AND HEPATOPROTECTIVE EFFECTS OF FISETIN ON ACUTE MURINE TOXOPLASMOSIS. EKB Journal Management System, 2021; 51(1): 79-88. doi: 10.21608/jesp.2021.165943

AMELORATIVE AND HEPATOPROTECTIVE EFFECTS OF FISETIN ON ACUTE MURINE TOXOPLASMOSIS

Journal of the Egyptian Society of Parasitology
Article 11, Volume 51, Issue 1, April 2021, Page 79-88  XML PDF (923.03 K)
Document Type: Original Article
DOI: 10.21608/jesp.2021.165943
View on SCiNiTO View on SCiNiTO
Authors
DALIA A. ELMEHY1; AMINA M. SALAMA2; NEMA A. SOLIMAN3; REEM A. ELKHOLY4; DINA M. TAHOON5; RASHA F.Department of Medical Parasitology MADY6; GHADA A. GAMEA2
1Departments of Medical Parasitology,
2Departments of Medical Parasitology
3Departments of Medical Biochemistry
4Departments of Medical Pharmacology
5Departments of Medical Pharmacology
6Department of Medical Parasitology
Abstract
Toxoplasma gondii (T. gondii) protozoan invades any nucleated cell with a special predilection to
reticuloendothelial cells. Liver is severely affected during acute toxoplasmosis. Promisingly, fisetin
(FIS) flavonoid was proved to have antioxidant, anti-inflammatory, anti-cancerous, and anti-protozoal
effects. This study was designed to evaluate the anti-Toxoplasma effect and the hepatoprotective potential
of FIS in vivo. Mice were infected with the virulent RH strain of T. gondii in a dose of
1x103tachyzoites/mouse. Mice were divided into seven equal groups: G1: healthy control, G2: infected
control, G3: Pyrimethamine® (PYR)/sulfadiazine (SDZ)), G4: oral-FIS, G5: oral-FIS+ PYR treated,
G6: intraperitoneal (I.P) FIS, and G7: I.P FIS+PYR treated. Survival rate was estimated, and tachyzoites
were counted in liver impression smears. Liver enzymes and C reactive protein (CRP) were measured
in mice sera. Liver tissues were examined for inflammatory mediators; cyclooxygenase 2 (COX-
2), interleukin (IL) -10, IL-12, IL- , oxidative mediators; inducible nitric oxide synthase (iNOS),
myeloperoxidase (MPO), and malondialdehyde (MDA) FIS showed a moderate effect on parasite survival
and tachyzoites count, with an excellent effect in reducing serum liver enzymes activity and proinflammatory
mediators. Combined (FIS+PYR) showed the best anti-parasitic and hepatoprotective
actions. Its administration I.P. gave significant cure compared to oral route. FIS when given I.P than
oral FIS had a good anti-inflammatory and antioxidant effect, decreased inflammatory cytokines and
improved hepatic pathology of acute toxoplasmosis. Combined FIS/PYR was the best drug regimen.
Keywords
Toxoplasma gondii, Fisetin, Arginase inhibitor, Oxidative stress, iNOS; Interleukins, Liver enzymes
Statistics
Article View: 387
PDF Download: 429